非达霉素治疗艰难梭菌感染的重症患者。
Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.
作者信息
Penziner Samuel, Dubrovskaya Yanina, Press Robert, Safdar Amar
机构信息
New York University Langone Medical Center and New York University School of Medicine, New York, New York.
New York University Langone Medical Center and New York University School of Medicine, New York, New York
出版信息
Antimicrob Agents Chemother. 2015 Mar;59(3):1776-81. doi: 10.1128/AAC.04268-14. Epub 2014 Dec 22.
Abstract
Fidaxomicin use to treat proven Clostridium difficile infection (CDI) was compared between 20 patients receiving care in critical care units (CCUs) and 30 patients treated on general medical floors. At baseline, the CCU patients had more initial CDI episodes, more severe and complicated disease, and more concurrent broad-spectrum antibiotic coverage. On multivariate analysis, the response to fidaxomicin therapy among the critically ill patients was comparable to that among patients in the general medical wards.
摘要
在重症监护病房（CCU）接受治疗的20例患者与普通内科病房治疗的30例患者之间，比较了非达霉素用于治疗已确诊的艰难梭菌感染（CDI）的情况。基线时，CCU患者有更多的初始CDI发作、更严重和复杂的疾病以及更多的同时使用广谱抗生素覆盖。多变量分析显示，重症患者对非达霉素治疗的反应与普通内科病房患者相当。
相似文献
1
Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.非达霉素治疗艰难梭菌感染的重症患者。
Antimicrob Agents Chemother. 2015 Mar;59(3):1776-81. doi: 10.1128/AAC.04268-14. Epub 2014 Dec 22.
2
Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin. fidaxomicin 治疗的住院患者可减少艰难梭菌的环境污染。
J Hosp Infect. 2015 Jul;90(3):267-70. doi: 10.1016/j.jhin.2015.01.015. Epub 2015 Feb 9.
3
Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.非达霉素：一种极少被吸收的大环脂类抗生素，用于治疗艰难梭菌感染。
Expert Rev Anti Infect Ther. 2013 Aug;11(8):767-76. doi: 10.1586/14787210.2013.814767.
4
Fidaxomicin for the treatment of Clostridium difficile infections. fidaxomicin 治疗艰难梭菌感染。
Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7.
5
Fidaxomicin--the new drug for Clostridium difficile infection.非达霉素——治疗艰难梭菌感染的新药。
Indian J Med Res. 2015 Apr;141(4):398-407. doi: 10.4103/0971-5916.159251.
6
Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.非达霉素用于临床实践中艰难梭菌感染的治疗：法国一家大学医院的前瞻性队列研究
Infection. 2017 Aug;45(4):425-431. doi: 10.1007/s15010-017-0981-8. Epub 2017 Jan 24.
7
Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.西班牙对非达霉素治疗特殊人群（癌症患者、合并抗生素治疗患者或肾功能损害患者）艰难梭菌感染（CDI）的经济学评估。
Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2213-23. doi: 10.1007/s10096-015-2472-0. Epub 2015 Sep 25.
8
Fidaxomicin, a new treatment for Clostridium difficile infections.非达霉素，一种治疗艰难梭菌感染的新疗法。
Drugs Today (Barc). 2012 Feb;48(2):101-8. doi: 10.1358/dot.2012.48.2.1746740.
9
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?艰难梭菌感染的现有和新兴治疗选择：非达霉素的作用是什么？
Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35. doi: 10.1111/1469-0691.12012.
10
Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.非达霉素：一种新型的大环内酯类抗生素，用于治疗艰难梭菌感染。
Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371.
引用本文的文献
1
Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review.与万古霉素、甲硝唑和粪菌移植相比，非达霉素的临床和经济结果：一项系统文献综述。
Medicine (Baltimore). 2024 Dec 27;103(52):e39219. doi: 10.1097/MD.0000000000039219.
2
Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives.危重症患者粪便微生物移植——系统评价与展望。
Biomolecules. 2021 Oct 4;11(10):1459. doi: 10.3390/biom11101459.
3
Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection.非达霉素作为暴发性艰难梭菌感染的挽救疗法
Cureus. 2021 Jul 22;13(7):e16559. doi: 10.7759/cureus.16559. eCollection 2021 Jul.
4
Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement.艰难梭菌（以前称为艰难梭状芽孢杆菌）感染的危重症患者：专家声明。
Intensive Care Med. 2020 Feb;46(2):215-224. doi: 10.1007/s00134-019-05873-x. Epub 2020 Jan 14.
5
Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI.医生，我的患者患有艰难梭菌感染（CDI），应该继续接受抗生素治疗。存在复发性艰难梭菌感染的（未解决的）风险。
Rev Esp Quimioter. 2019 Sep;32 Suppl 2(Suppl 2):47-54.
6
[Recommendations from a panel of experts on the usefulness of fidaxomicin for the treatment of infections caused by Clostridium difficile].[艰难梭菌感染治疗中菲达霉素效用的专家小组建议]
Rev Esp Quimioter. 2019 Feb;32(1):50-59. Epub 2018 Dec 13.
7
Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.口服替考拉宁与口服万古霉素治疗严重艰难梭菌感染：一项前瞻性观察研究。
Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):745-754. doi: 10.1007/s10096-017-3169-3. Epub 2018 Jan 3.
8
Sleeping with the enemy: Clostridium difficile infection in the intensive care unit.与敌同眠：重症监护病房中的艰难梭菌感染。
Crit Care. 2017 Oct 22;21(1):260. doi: 10.1186/s13054-017-1819-6.
9
Infections in Cancer Patients with Solid Tumors: A Review.实体瘤癌症患者的感染：综述
Infect Dis Ther. 2017 Mar;6(1):69-83. doi: 10.1007/s40121-017-0146-1. Epub 2017 Feb 3.
10
Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.非达霉素用于临床实践中艰难梭菌感染的治疗：法国一家大学医院的前瞻性队列研究
Infection. 2017 Aug;45(4):425-431. doi: 10.1007/s15010-017-0981-8. Epub 2017 Jan 24.
本文引用的文献
1
Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies.ICU 中 VRE 定植的趋势和意义：已发表研究的荟萃分析。
PLoS One. 2013 Sep 27;8(9):e75658. doi: 10.1371/journal.pone.0075658. eCollection 2013.
2
Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.利福昔明与常规抗菌治疗在 59 例接受实体器官和造血干细胞移植并发艰难梭菌相关性腹泻患者中的疗效比较。
Antimicrob Agents Chemother. 2013 Sep;57(9):4501-5. doi: 10.1128/AAC.01120-13. Epub 2013 Jul 8.
3
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.与万古霉素相比， fidaxomicin 治疗艰难梭菌感染可减少耐万古霉素肠球菌和念珠菌属的定植和过度生长。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S121-6. doi: 10.1093/cid/cis440.
4
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. fidaxomicin 与万古霉素治疗欧洲、加拿大和美国艰难梭菌感染：一项双盲、非劣效、随机对照试验。
Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.
5
Comparative effectiveness of Clostridium difficile treatments: a systematic review.艰难梭菌治疗方法的疗效比较：系统评价。
Ann Intern Med. 2011 Dec 20;155(12):839-47. doi: 10.7326/0003-4819-155-12-201112200-00007.
6
Clostridium difficile infection in HIV-seropositive individuals and transplant recipients.HIV 血清阳性个体和移植受者中的艰难梭菌感染。
J Infect. 2012 Feb;64(2):131-47. doi: 10.1016/j.jinf.2011.12.003. Epub 2011 Dec 9.
7
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. fidaxomicin 与万古霉素治疗同时使用抗生素治疗其他合并感染的个体中艰难梭菌感染的疗效。
Clin Infect Dis. 2011 Sep;53(5):440-7. doi: 10.1093/cid/cir404.
8
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. fidaxomicin 和其主要代谢产物 OP-1118 对艰难梭菌的抗生素后效应。
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
9
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).艰难梭菌感染临床实践指南：美国医疗保健流行病学学会（SHEA）和美国传染病学会（IDSA）2010 年更新版。
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.
Zotero 插件